Evotec AG and the Jain Foundation, Inc. have further extended their collaboration to include the screening of compound libraries in multiple assay formats to support Jain’s discovery efforts for dysferlinopathies, an inherited skeletal muscular dystrophy diseases. Financial terms were not disclosed.
 
Dr. Mario Polywka, chief operating officer of Evotec, said, “We are delighted to continue our relationship with the Jain Foundation and to be a part of this important step in dysferlin research. The progress to date and initiation of multiple screening programs is a major accomplishment for both organizations and demonstrates Evotec’s growing role in driving innovative and industrialized research in partnership with foundations such as the Jain Foundation working in rare diseases.”
 
Dr. Plavi Mittal, president and chief executive officer of Jain Foundation, added: “We are pleased with the progress of our project with Evotec to date, and are excited to move forward to the screening phase of our drug development program.”